We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




RNA Biomarker Assay Now Manufactured According to Strict ISO Regulatory Criteria

By LabMedica International staff writers
Posted on 19 Aug 2014
Print article
Image: RNAscope detects TP63 mRNA expression in human prostate tissue (Photo courtesy of Advanced Cell Diagnostics).
Image: RNAscope detects TP63 mRNA expression in human prostate tissue (Photo courtesy of Advanced Cell Diagnostics).
A line of diagnostic kits that measures RNA biomarkers with single-molecule sensitivity is now being manufactured under the stringent requirements of ISO 13485:2003 certification.

Advanced Cell Diagnostics, Inc. (Hayward, CA, USA), a global technology and market leader in in situ nucleic acid detection for life science research and clinical diagnostics, announced that the production facility for its line of RNAscope assays has received ISO 13485:2003 certification. ISO 13485:2003 certification, issued by the International Organization for Standardization (Geneva, Switzerland), the world's largest developer and publisher of international standards, regulates design, development, production, and commercialization for the implementation of quality management systems and various other technical and operational procedures.

Radioscope technology is the first automated multiplex RNA in situ hybridization platform capable of detecting and quantifying RNA biomarkers with single-molecule sensitivity. RNA expression levels are highly dynamic and integrate both genetic and epigenetic mechanisms of gene regulation. Thus, RNA expression reflects the state of a biological system. Measuring RNA biomarkers as RNA provides the most direct route for biomarker validation and assay development.

RNAscope employs a proven design strategy similar to fluorescence resonance energy transfer (FRET), in which two independent probes (double Z probes) must hybridize to the target sequence in tandem in order for signal amplification to occur. Because it is highly unlikely that two independent probes will hybridize to a nonspecific target right next to each other, this design concept ensures selective amplification of target-specific signals. For each target RNA species, 20 double Z target probe pairs are designed to specifically hybridize to the target molecule, but not to nontargeted molecules.

"Advanced Cell Diagnostics' vision is to make RNAscope the PCR equivalent for in situ nucleic acid detection and drive adoption of this technology in diagnostic tests," said Dr.Yuling Luo, president and CEO of Advanced Cell Diagnostics. "This ISO certification is the first step in our quality systems road map, which is designed to ensure that we supply products of the highest quality to our customers and provide a seamless path for our partners to translate scientific advances to patient benefits."

Related Links:

Advanced Cell Diagnostics, Inc.
International Organization for Standardization


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.